Reference Values for 27 Clinical Chemistry Tests in 70-Year-Old Males and Females

Lena Carlsson^a Lars Lind^b Anders Larsson^a

Department of Medical Sciences, ^aClinical Chemistry and ^bInternal Medicine, Uppsala University, Uppsala, Sweden

Key Words

70-year-old population • Reference values • Biological markers

Abstract

Background: Reference values are usually defined based on blood samples from healthy men or nonpregnant women in the age range of 20–50 years. These values are not optimal for elderly patients, as many biological markers change over time and adequate reference values are important for correct clinical decisions. **Objective:** To validate NORIP (Nordic Reference Interval Project) reference values in a 70-year-old population. **Methods:** We studied 27 frequently used laboratory tests. The 2.5th and 97.5th percentiles for these markers were calculated according to the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values. **Results:** Reference values are reported for plasma alanine aminotransferase, albumin, alkaline phosphatase, pancreas amylase, apolipoprotein A1, apolipoprotein B, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, creatinine, creatine kinase, C-reactive protein, glucose, γ -glutamyltransferase, HDL-cholesterol, iron, lactate dehydrogenase, LDL-cholesterol, magnesium, phosphate, potassium, sodium, transferrin, triglycerides, urate and urea. **Conclusion:** Reference values calculated from the whole population and a subpopulation without cardiovascular disease showed strong concordance. Several of the reference interval limits were outside the 90% CI of a Scandinavian population (NORIP).

Introduction

Today, there are a limited number of instruments suited for high-throughput clinical use. Results from internal and external quality assessment programs confirm that there are acceptable interlaboratory agreements [1]. In principle it should be possible to have the same reference values, independent of which laboratory performs the measurements. There is currently a trend to establish common reference values where possible [2, 3]. Increasing national and international communication between healthcare providers also strengthens the need for the harmonization of measurements and reference values in laboratories [4].

Presently, only a few clinical laboratories produce their own reference values, with the great majority using reference values from the literature [5]. The use of such reference values shows the need for publications that present reference values based on modern methods. Such publications should include not only the reference value, but also provide information regarding reference population, methods used, traceability and imprecision. Without such information, it is difficult to transfer and use published reference values in other laboratories. Unfortunately, many publications on reference values lack one or several of these important pieces of information.

Reference values are usually given for each sex, but may not take into account variation in reference values due to age. Many biomarkers change with age and, therefore, reference values based on a population in the age

Copyright © 2009 S. Karger AG, Basel

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2009 S. Karger AG, Basel
0304-324X/10/0563-0259\$26.00/0

Accessible online at:
www.karger.com/ger

Anders Larsson
Department of Medical Sciences
University Hospital
SE-751 85 Uppsala (Sweden)
Tel. +46 18 611 4271, Fax +46 18 552 562, E-Mail anders.larsson@akademiska.se

Table 1. Total analytical imprecision for the method used to calculate the reference values

Analyte	Concentration	CV, %
Alanine aminotransferase, $\mu\text{kat/l}$	0.76	2.1
	1.9	1.9
Albumin, g/l	32	0.3
	49	0.4
Alkaline phosphatase, $\mu\text{kat/l}$	2.3	1.8
	10.6	1.6
Amylase (pancreas), $\mu\text{kat/l}$	1	0.5
	0.3	1.1
Apolipoprotein A1, g/l	0.68	1.8
	2.0	1.2
Apolipoprotein B, g/l	0.47	4.5
	1.68	2.4
Bilirubin, $\mu\text{mol/l}$	10	2.5
	26	2.7
Calcium, mmol/l	2.2	0.9
	2.9	1.2
Chloride, mmol/l	85	0.7
	108	0.5
Cholesterol, mmol/l	5.7	0.5
	7.8	0.6
Creatinine, $\mu\text{mol/l}$	70	4.8
	94	4.8
Creatinine kinase, $\mu\text{kat/l}$	1.8	1.4
	2.8	0.7
C-reactive protein, mg/l	2.6	1.4
	8	0.8
γ -Glutamyltransferase, $\mu\text{kat/l}$	1.3	0.7
	2.4	0.9
HDL-cholesterol, mmol/l	0.9	2.3
	1.2	2.1
Iron, $\mu\text{mol/l}$	18	0.9
	37	1.7
Lactate dehydrogenase, $\mu\text{kat/l}$	1.25	1.3
	2.7	1.0
LDL-cholesterol, mmol/l	1.6	1.0
	2.8	1.1
Magnesium, mmol/l	0.9	1.4
	1.7	0.9
Phosphate, mmol/l	1.1	0.6
	1.7	0.5
Potassium, mmol/l	3.3	1.5
	5.5	1.0
Sodium, mmol/l	114	0.8
	141	0.6
Transferrin, g/l	2.0	0.7
	3.0	0.8
Triglycerides, mmol/l	0.9	1.1
	2.2	1.1
Urate, $\mu\text{mol/l}$	280	2.1
	580	0.7
Urea, mmol/l	5.3	0.6
	11.1	0.6

CV = Coefficient of variation.

range of 20–50 years may not be appropriate for 70-year-old patients.

Clinical chemistry reference values for elderly persons are sparse and often intermixed with those of younger subjects. Elderly patients are often treated by the health care system, and they seek health care more often than those who are 20–50 years of age. The approximate median age of patients treated in most hospital wards is 70 years. Since appropriate reference values are essential for quality patient care, we felt an urge to set up reference values for our most widely used serum analytes representative for our elderly patients. The criteria for defining a ‘healthy’ population for establishing reference values vary. If very strict criteria are used in an elderly population, the group may become very small and not very representative of the whole population. Many elderly individuals are on some type of medication and often have symptoms of cardiovascular disease (CVD). When we set up the selection criteria for this study, we decided to exclude all individuals with diabetes and then calculate reference values. The aim of the study was to validate reference values from the Nordic Reference Interval Project (NORIP) in a 70-year-old population.

Subjects and Methods

Subjects

All subjects aged 70 years living in Uppsala, Sweden, were eligible. The subjects were chosen from the community register and were invited to participate in a randomized order from the start of the study in April 2001 to the last included subject in June 2005. The subjects received an invitation by letter within 1 month of their 70th birthday in order to standardize for age. Of the 2,025 subjects invited, 1,016 subjects were investigated, resulting in a participation rate of 50.1%. The study is part of the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study [6].

The study was approved by the ethics committee of the University of Uppsala, and the participants gave their informed consent.

The participants were asked to answer a questionnaire about their medical history, smoking habits and regular medication. All subjects were investigated in the morning after an overnight fast. No medication or smoking was allowed after midnight. During the investigation, the subjects were supine in a quiet room maintained at a constant temperature. CVD was defined as myocardial infarction, stroke and heart failure, but not hypertension.

Blood glucose was analyzed in whole blood on a HemoCue instrument (HemoCue®, Ängelholm, Sweden) with reagents from the manufacturer. Blood samples were collected in Vacutainer tubes without additives. Total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were centrifuged at room temperature in a Genesis FE500 (Tecan, Männedorf, Switzerland) and analyzed on the day the samples were collected. Samples for the

Table 2. Traceability of the standardizations of the methods used to calculate the reference values

Method and reagent	Standardization	Methodology
Alanine aminotransferase (8D36-30)	BM masterlot	activated alanine aminotransferase [7]
Albumin (7D54-20)	BM masterlot	bromocresol purple
Alkaline phosphatase (7D55-30)	BM masterlot	paranitrophenyl phosphate
Amylase (pancreas) (6K2201-01)	Equalis	EPS substrate, antibody-blocked salivary amylase
Apolipoprotein A1 (9D92-01)	WHO/IFCC/CDC	immunoturbidimetry
Apolipoprotein B (9D92-01)	WHO/IFCC/CDC	immunoturbidimetry
Bilirubin (11489494, RD)	BM masterlot	diazotized sulfanilic acid
Calcium (1125621, RD)	BM masterlot	orthocresolphthalein dye
Chloride (9D28)	NIST SRM 909	ion selective electrode
Cholesterol (7D62-20)	BM masterlot	cholesterol oxidase
Creatinine (14.3600.01, SI)	BM masterlot	compensated Jaffe
Creatinine kinase (7D63-20)	BM masterlot	NAC (N-acetyl-L-cysteine)
C-reactive protein (6K2601)	CRM 470	Latex-enhanced immunoturbidimetry
γ -Glutamyltransferase (7D65-20)	BM masterlot	L- γ -glutamyl-3-carboxy-4-nitroanilide
HDL-cholesterol (3K33-20)	CDC Abell-Kendall	accelerator selective detergent
Iron (6K9510)	BM masterlot	ferrozine (ferene S)
Lactate dehydrogenase (7D69-20)	BM masterlot	lactate to pyruvate (NADH)
LDL-cholesterol (1E31-20)	NRS/CHOL	homogenous direct LDL method
Magnesium (11489330, RD)	BM masterlot	xylidyl blue
Phosphate (7D71-30)	BM masterlot	phosphomolybdate
Potassium (9D28)	NIST SRM 909	ion selective electrode
Sodium (9D28)	NIST SRM 909	ion selective electrode
Transferrin (1E04-01)	CAP/BCR/IFCC	immunoturbidimetry
Triglycerides (7D74-20)	BM masterlot	
Urate (7D76-20)	BM masterlot	uricase
Urea (7D75-20)	BM masterlot	urease

Analyte, reagents (within brackets), methodology and traceability of the standardizations of the methods used to calculate the reference intervals. If not stated otherwise, all reagents were from Abbott Laboratories. RD = Roche Diagnostics (Mannheim, Germany); SI = Synermed International (Westfield, Ind., USA).

other analytes were centrifuged in a refrigerated centrifuge and stored at -80°C until analysis. Samples from individuals with a diagnosis of diabetes mellitus or a fasting plasma glucose ≥ 7.0 mmol/l were excluded from the study.

Instrument

All measurements were performed on an Architect Ci8200 analyzer (Abbott Laboratories, Abbott Park, Ill., USA) and reported using SI units. Total analytical imprecision of the assays is presented in table 1. Traceability of the methods is presented in table 2.

The Nordic Reference Interval Project

NORIP, established in March 1998 (www.furst.no/norip/), was initiated to establish common Nordic reference intervals for 25 of the most frequently requested analytes in clinical biochemistry [8]. The reference material is based on 3,035 reference individuals (47% males, 53% females). The majority of the individuals were of Nordic origin (96%). The age distribution of the NORIP population was: 18–30 years for 793, 31–50 years for 928, 51–70 years for 832 and >70 years for 449 subjects.

Statistical Calculations

Calculations of reference values were performed by bootstrap estimation, utilizing RefVal 4.0 (Department of Clinical Chemistry, Rikshospitalet, Oslo, Norway). RefVal fulfils the recommendations of the International Federation of Clinical Chemistry for the statistical treatment of reference values [9, 10]. Comparisons between groups were performed with a Mann-Whitney U test (Statistica, StatSoft, Tulsa, Okla., USA). For comparisons between the reference values in NORIP and the reference intervals obtained in this study, 90% confidence intervals were used.

Results

Description of the Study Population

Basic characteristics of the total samples based on the questionnaire are presented in table 3. Approximately 10% of the cohort reported a history of coronary heart disease, 4% reported stroke and 9% diabetes mellitus.

Table 3. Basic characteristics of the total sample (n = 1,016)

Variable	Mean $\pm$ SD
Females, %	50.2
Height, cm	169 $\pm$ 9.1
Weight, kg	77 $\pm$ 14
Waist circumference, cm	91 $\pm$ 12
BMI	27.0 $\pm$ 4.3
Waist/hip ratio	0.90 $\pm$ 0.075
SBP, mm Hg	150 $\pm$ 23
DBP, mm Hg	79 $\pm$ 10
Myocardial infarction, %	7.1
Stroke, %	3.7
Angina pectoris, %	8.1
Congestive heart failure, %	3.8
Diabetes, %	8.7
Current smoking, %	11
Any regular drug, %	70
Any cardiovascular drug, %	45
Any antihypertensive medication, %	32
β -Blockers, %	22
Calcium antagonists, %	11
Diuretics, %	13
ACE-inhibitors, %	8.5
Angiotensin II blockers, %	8.3
Digoxin, %	2.1
Statins, %	15
Insulin, %	1.8
Oral antidiabetic drugs, %	6.1
Aspirin/clopidogrel, %	18

The majority had regular medication (70%). Almost half the cohort reported some type of cardiovascular medication (45%), with antihypertensive medication being the most prevalent (32%). Fifteen percent reported use of statins, while insulin and oral antiglycemic drugs were reported in 2 and 6%, respectively. After excluding individuals with known diabetes mellitus and individuals with a fasting plasma glucose ≥ 7.0 mmol/l, the study population consisted of 459 females and 438 males. 51 females and 88 males had a history of CVD (myocardial infarction, stroke and heart failure, but not hypertension).

Mann-Whitney Tests Comparing Individuals with and without CVD

For females, only transferrin, triglycerides and urate showed significant differences between the groups at the $p = 0.05$ level. For males, albumin, apolipoprotein A1, apolipoprotein B, total cholesterol, HDL-cholesterol,

LDL-cholesterol, calcium, creatinine, urate and urea showed significant differences between the groups.

Reference Values

The 2.5th and 97.5th percentiles for each subgroup are presented in table 4 together with the corresponding values according to NORIP [8].

Reference values calculated from the whole population and a subpopulation without CVD showed strong concordance. Only the lower limit of the reference values for cholesterol and LDL-cholesterol for all men were outside the 90% CI for males without CVD.

In the present study, the upper reference limit for alanine aminotransferase in men was significantly lower than the values reported in NORIP [8]. The lower reference values for albumin and alkaline phosphatase were slightly lower, while the upper reference interval for amylase was below the 90% CI reported in NORIP. The upper reference interval for bilirubin was lower, while the upper reference interval for calcium was higher. In total, 5.3% of the samples had values over 2.60, and 10.2% of the values were higher than the upper reference limit in NORIP (2.51 mmol/l). We also found lower creatinine values than in NORIP, which could indicate lower muscle mass or better kidney function in our cohort. Differences for the upper limits of the reference intervals for lactate dehydrogenase, sodium and urate were observed as well. Thus, the reference values obtained in the present study differed from NORIP for several of the studied analytes.

Discussion

Setting up reference values representative of local service populations is a major responsibility for clinical laboratories. Such reference values often contain few or no individuals older than 65 years of age. Following the recommendations of the International Federation of Clinical Chemistry, we have established reference values based on 70-year-old healthy males and females for a group of common serum analytes. The study population was recruited in the county of Uppland, Sweden. Diabetes and elevated fasting plasma glucose were used as exclusion criteria for the study. Elderly individuals often have illnesses or are on some type of medication. The number of individuals with CVD or taking cardiovascular medication increases with age, and the prevalence in certain elderly populations may be very high. In this population, 70% used medication regularly and almost half the population used cardiovascular drugs. If such individuals are excluded, the end result may

Table 4. Calculated upper (97.5th percentile) and lower (2.5th percentile) limits for the reference interval and 90% CI (in brackets)

Analyte	Lower limit	Upper limit	Analyte	Lower limit	Upper limit
Alanine aminotransferase, $\mu\text{kat/l}$			Chloride, mmol/l^b		
Males, all	<0.15 ^a	0.74 (0.65–0.82)	Males, all	103 (102–104)	122 (118–125)
Males, without CVD	<0.15 ^a	0.72 (0.61–0.83)	Males, without CVD	103 (102–104)	119 (114–124)
Females, all	<0.15 ^a	0.80 (0.68–0.93)	Females, all	103 (102–103)	120 (118–123)
Females, without CVD	<0.15 ^a	0.84 (0.67–1.01)	Females, without CVD	103 (102–104)	120 (118–123)
<i>NORIP</i>					
Males, >18 years	0.17 (0.15–0.18)	1.13 (1.05–1.23)	Cholesterol, mmol/l		
Females, >18 years	0.13 (0.11–0.14)	0.77 (0.72–0.82)	Males, all	3.4 (3.2–3.6)	7.2 (7.0–7.5)
Albumin, g/l			Males, without CVD	3.7 (3.5–3.9)	7.3 (7.0–7.6)
Males, all	35.4 (34.9–36.0)	47.5 (46.7–48.2)	Females, all	4.0 (3.8–4.2)	7.7 (7.5–7.9)
Males, without CVD	35.6 (35.0–36.1)	46.9 (45.7–48.2)	Females, without CVD	4.0 (3.8–4.2)	7.7 (7.5–7.9)
Females, all	35.8 (35.2–36.4)	46.2 (45.4–47.1)	<i>NORIP</i>		
Females, without CVD	35.8 (35.2–36.4)	46.3 (45.5–47.1)	Males and females, >50 years	4.0 (4.0–4.1)	7.9 (7.7–8.1)
<i>NORIP</i>					
Males and females, 40–69 years	36.5 (36.3–36.7)	47.9 (47.5–48.4)	Creatinine, $\mu\text{mol/l}$		
Alkaline phosphatase, $\mu\text{kat/l}$			Males, all	59 (57–60)	125 (116–133)
Males, all	0.52 (0.48–0.56)	1.65 (1.49–1.81)	Males, without CVD	59 (57–60)	122 (113–130)
Males, without CVD	0.52 (0.48–0.57)	1.65 (1.46–1.83)	Females, all	45 (44–47)	103 (99–107)
Females, all	0.51 (0.49–0.55)	1.69 (1.61–1.77)	Females, without CVD	45 (43–48)	102 (97–106)
Females, without CVD	0.52 (0.49–0.55)	1.70 (1.62–1.78)	<i>NORIP</i>		
<i>NORIP</i>			Males, >18 years	64 (63–64)	100 (99–101)
Males and females, >18 years	0.62 (0.60–0.65)	1.77 (1.68–1.88)	Females, >18 years	51 (50–52)	84 (83–87)
Amylase (pancreas), $\mu\text{kat/l}$					
Males, all	0.16 (0.14–0.18)	0.82 (0.75–0.89)	Creatinine kinase, $\mu\text{kat/l}$		
Males, without CVD	0.17 (0.14–0.19)	0.83 (0.76–0.90)	Males, all	0.49 (0.39–0.58)	4.98 (4.24–5.72)
Females, all	0.17 (0.15–0.19)	0.93 (0.82–1.03)	Males, without CVD	0.49 (0.40–0.58)	4.81 (4.11–5.50)
Females, without CVD	0.17 (0.14–0.20)	0.92 (0.82–1.02)	Females, all	0.41 (0.35–0.46)	3.01 (2.78–3.30)
<i>NORIP</i>			Females, without CVD	0.41 (0.36–0.46)	3.02 (2.73–3.32)
Males and females, >18 years	0.18 (0.10–0.22)	1.07 (0.90–1.13)	<i>NORIP</i>		
Apolipoprotein A1, g/l^b			Males, >50 years	0.65 (0.60–0.77)	4.62 (4.20–6.73)
Males, all	1.10 (1.06–1.14)	2.15 (2.01–2.29)	Females, >18 years	0.55 (0.52–0.58)	3.45 (3.00–3.88)
Males, without CVD	1.11 (1.07–1.15)	2.18 (2.04–2.32)			
Females, all	1.27 (1.21–1.32)	2.45 (2.37–2.54)	C-reactive protein, mg/l^b		
Females, without CVD	1.26 (1.19–1.32)	2.46 (2.36–2.55)	Males, all	0.33 (0.27–0.39)	12.63 (9.11–16.14)
Apolipoprotein B, g/l^b			Males, without CVD	0.34 (0.27–0.40)	14.24 (9.69–18.78)
Males, all	0.62 (0.60–0.65)	1.54 (1.46–1.61)	Females, all	0.34 (0.29–0.40)	12.42 (8.53–16.32)
Males, without CVD	0.64 (0.61–0.67)	1.55 (1.44–1.66)	Females, without CVD	0.35 (0.28–0.41)	11.57 (8.93–14.21)
Females, all	0.70 (0.66–0.73)	1.57 (1.48–1.66)			
Females, without CVD	0.70 (0.67–0.74)	1.59 (1.50–1.69)	γ -Glutamyltransferase, $\mu\text{kat/l}$		
Bilirubin, $\mu\text{mol/l}$			Males, all	0.18 (0.17–0.20)	1.91 (1.55–2.27)
Males, all	4.9 (4.5–5.4)	23.9 (21.9–26.0)	Males, without CVD	0.18 (0.16–0.20)	1.73 (1.42–2.04)
Males, without CVD	5.0 (4.4–5.6)	23.1 (19.9–26.3)	Females, all	0.14 (0.13–0.15)	1.20 (1.02–1.39)
Females, all	3.8 (3.4–4.1)	16.4 (13.8–19.0)	Females, without CVD	0.14 (0.13–0.15)	1.23 (1.02–1.44)
Females, without CVD	3.9 (3.5–4.2)	16.4 (13.7–19.1)	<i>NORIP</i>		
<i>NORIP</i>			Males, >40 years	0.25 (0.23–0.27)	1.90 (1.65–2.23)
Males and females, >18 years	4.7 (4.5–5.0)	24.0 (23.1–25.1)	Females, >40 years	0.18 (0.17–0.18)	1.13 (1.05–1.23)
Calcium, mmol/l					
Males, all	2.17 (2.15–2.19)	2.67 (2.60–2.74)	HDL-cholesterol, mmol/l		
Males, without CVD	2.17 (2.15–2.19)	2.66 (2.58–2.74)	Males, all	0.8 (0.7–0.9)	2.2 (2.0–2.3)
Females, all	2.18 (2.16–2.20)	2.70 (2.64–2.77)	Males, without CVD	0.8 (0.7–0.9)	2.2 (2.0–2.4)
Females, without CVD	2.18 (2.15–2.20)	2.70 (2.63–2.76)	Females, all	1.0 (1.0–1.1)	2.8 (2.6–3.0)
<i>NORIP</i>			Females, without CVD	1.0 (1.0–1.1)	2.8 (2.5–3.0)
Males and females, >18 years	2.17 (2.17–2.18)	2.51 (2.50–2.52)	<i>NORIP</i>		
			Males, >18 years	0.8 (0.8–0.9)	2.1 (2.1–2.2)
			Females, >18 years	1.0 (1.0–1.1)	2.6 (2.5–2.7)
			Iron, $\mu\text{mol/l}$		
			Males, all	10.3 (9.5–11.2)	32.8 (29.8–35.7)
			Males, without CVD	10.6 (9.8–11.5)	33.6 (30.3–36.9)
			Females, all	10.3 (9.7–10.9)	30.0 (28.5–31.4)
			Females, without CVD	10.5 (9.9–11.0)	30.0 (28.4–31.5)
			<i>NORIP</i>		
			Males and females, >18 years	9.2 (8.9–9.6)	33.7 (33.0–34.4)

Table 4 (continued)

Analyte	Lower limit	Upper limit	Analyte	Lower limit	Upper limit
Lactate dehydrogenase, $\mu\text{kat/l}$			Sodium, mmol/l		
Males, all	1.6 (1.5–1.7)	3.8 (3.4–3.8)	Males, all	136 (136–137)	157 (152–162)
Males, without CVD	1.6 (1.5–1.7)	3.8 (3.4–4.2)	Males, without CVD	136 (136–137)	156 (150–161)
Females, all	1.5 (1.3–1.7)	3.9 (3.5–4.3)	Females, all	137 (136–137)	158 (155–161)
Females, without CVD	1.4 (1.3–1.6)	3.8 (3.5–4.2)	Females, without CVD	137 (136–138)	158 (155–161)
NORIP			NORIP		
Males and females, 18–69 years	1.7 (1.5–1.8)	3.4 (3.3–3.5)	Males and females, >18 years	137 (136–137)	145 (144–145)
LDL-cholesterol, mmol/l			Transferrin, g/l ^b		
Males, all	1.76 (1.62–1.90)	5.05 (4.87–5.23)	Males, all	1.72 (1.65–1.78)	3.08 (2.97–3.19)
Males, without CVD	1.93 (1.82–2.04)	5.11 (4.82–5.41)	Males, without CVD	1.70 (1.63–1.76)	3.00 (2.92–3.09)
Females, all	2.05 (1.90–2.21)	5.31 (5.14–5.48)	Females, all	1.74 (1.64–1.85)	3.12 (3.00–3.23)
Females, without CVD	2.10 (1.93–2.27)	5.33 (5.10–5.55)	Females, without CVD	1.74 (1.65–1.83)	3.04 (2.90–3.18)
NORIP					
Males and females, >50 years	1.98 (1.86–2.16)	5.35 (5.13–5.67)	Triglycerides, mmol/l		
Magnesium, mmol/l			Males, all	0.52 (0.50–0.54)	2.72 (2.32–3.12)
Males, all	0.70 (0.68–0.72)	0.96 (0.93–0.98)	Males, without CVD	0.51 (0.47–0.55)	2.80 (2.23–3.36)
Males, without CVD	0.70 (0.68–0.71)	0.96 (0.93–0.99)	Females, all	0.52 (0.47–0.57)	2.63 (2.48–2.78)
Females, all	0.71 (0.69–0.72)	0.96 (0.95–0.98)	Females, without CVD	0.52 (0.48–0.57)	2.60 (2.44–2.75)
Females, without CVD	0.70 (0.68–0.72)	0.96 (0.94–0.98)	NORIP		
NORIP			Males and females, >18 years	0.47 (0.44–0.48)	2.60 (2.35–2.86)
Males and females, >18 years	0.71 (0.70–0.71)	0.94 (0.93–0.95)	Urate, $\mu\text{mol/l}$		
Phosphate, mmol/l			Males, all	237 (222–253)	551 (525–577)
Males, all	0.77 (0.74–0.80)	1.33 (1.30–1.36)	Males, without CVD	234 (221–246)	529 (506–551)
Males, without CVD	0.78 (0.74–0.81)	1.33 (1.31–1.36)	Females, all	189 (178–200)	471 (451–491)
Females, all	0.87 (0.83–0.91)	1.51 (1.48–1.54)	Females, without CVD	188 (175–201)	461 (448–475)
Females, without CVD	0.88 (0.85–0.92)	1.51 (1.48–1.54)	NORIP		
NORIP			Males, >18 years	231 (225–239)	475 (466–481)
Males, >50 years	0.75 (0.73–0.77)	1.33 (1.31–1.39)	Females, >50 years	154 (148–159)	394 (379–414)
Females, >18 years	0.85 (0.84–0.87)	1.49 (1.45–1.50)	Urea, mmol/l		
Potassium, mmol/l			Males, all	3.7 (3.4–3.9)	9.3 (8.5–10.0)
Males, all	3.3 (3.2–3.4)	4.5 (4.4–4.5)	Males, without CVD	3.7 (3.4–3.9)	8.8 (8.2–9.3)
Males, without CVD	3.2 (3.1–3.4)	4.5 (4.4–4.6)	Females, all	3.4 (3.3–3.5)	8.3 (8.0–8.5)
Females, all	3.3 (3.3–3.3)	4.5 (4.4–4.6)	Females, without CVD	3.4 (3.3–3.6)	8.2 (8.0–8.4)
Females, without CVD	3.3 (3.3–3.3)	4.5 (4.4–4.7)	NORIP		
NORIP			Males, >50 years	3.6 (3.5–3.8)	8.2 (8.0–8.4)
Males and females, >18 years	3.6 (3.6–3.6)	4.6 (4.6–4.7)	Females, >50 years	3.1 (3.0–3.3)	8.0 (8.0–8.4)

^a Denotes that the 90% CI could not be calculated as the instrument did not report ALT values <0.15 $\mu\text{kat/l}$, and several test results were <0.15. NORIP 2000 recommended reference intervals are provided for comparison.

^b Not determined in NORIP.

be a very small subpopulation. One could argue that such a small subpopulation is not representative of an elderly population. We thus decided to only exclude patients with diabetes and elevated fasting glucose, as most elderly populations in the study groups contain several individuals with a history of CVD or use of cardiovascular medication. Mann-Whitney tests comparing the groups with and without CVD showed that there were few significant differences between the 2 groups. However, even if there were significant differences between the groups, the 90% CI for the reference values was not separated.

For males, albumin, apolipoprotein A1, apolipoprotein B, cholesterol, HDL-cholesterol, LDL-cholesterol, calcium, creatinine, urate and urea showed significant differences between the total population and the group without CVD. However, only the lower limit of the lower reference values for cholesterol and LDL-cholesterol for all men were outside the 90% CI for males without CVD. The lower reference values for these analytes are usually of less importance than the upper reference values for clinical decisions.

The reference values with and without the CVD group are presented in table 4. We chose to divide the reference values according to sex, as most laboratory information systems handle sex-specific reference values. For several of the analytes, the sex differences are so small that the same reference interval could be used for both sexes. The reference values were compared with the corresponding values obtained in NORIP (presented in table 4) [8], and there were clear differences. In many cases, such differences are difficult to explain. The NORIP results increased the upper reference interval for alanine aminotransferase in men in most Swedish laboratories, while the pre-NORIP upper reference interval was similar to the one found in the present study. This could indicate that the NORIP limit is a bit high. NORIP also resulted in a lowering of the reference intervals for calcium [11]. There may be some unknown cases of hyperparathyroidism in our study group, but the number of individuals with increased calcium levels is too large to be explained by hyperparathyroidism alone. Thus, it seems that the NORIP reference interval for calcium is too low for this age group. NORIP had very rigorous criteria for blood sampling in comparison with clinical praxis [12]. This may have resulted in a bias, as stasis and similar methods are known to increase calcium values. How-

ever, there may also be a true difference as an earlier study reports approximately 0.05 mmol/l higher calcium in individuals >60 years [11]. The lower creatinine values in the present study are most likely due to the reduced muscle mass that occurs in elderly individuals.

The present sample is limited to Caucasians aged 70 years. Caution should therefore be made in drawing conclusions for other ethnic and age groups. The methods used in this study are specified in table 2. As the choice of method may influence the test results, the results in this study may not be representative for other types of methods.

In our opinion, reference values should be re-evaluated regularly (e.g. every 10 years) to ensure that the reference values are still appropriate for the patients of today. Sex- and age-specific reference values should be used to interpret results of laboratory screening tests.

Acknowledgement

This study was financially supported by the Uppsala University Hospital Research Fund.

References

- Mathias D, Gebhard J, Wilhelm L, Schmidt-Gayk H, Mathias I: 26 years of external quality controls for the screening of congenital metabolic disorders in newborns – a summary of the results. *Clin Lab* 2008;54:103–108.
- Fuentes-Arderiu X, Mas-Serra R, Aluà-Trullàs A, Mart-Marcet MI, Dot-Bach D; Catalan Association for Clinical Laboratory Sciences: Guideline for the production of multicentre physiological reference values using the same measurement system. A proposal of the Catalan Association for Clinical Laboratory Sciences. *Clin Chem Lab Med* 2004;42:778–782.
- Rustad P, Felding P, Lahti A: Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma. *Clin Chem Lab Med* 2004;42:783–791.
- Guidi GC, Lippi G, Solero GP, Poli G, Plebani M: Managing transferability of laboratory data. *Clin Chim Acta* 2006;374:57–62.
- Ferre-Masferrer M, Fuentes-Arderiu X, Puchal-Ane R: Indirect reference limits estimated from patients' results by three mathematical procedures. *Clin Chim Acta* 1999; 279:97–105.
- Lind L, Fors N, Hall J, Marttala K, Stenborg A: A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vascularity in Uppsala Seniors (PIVUS) study. *Arterioscler Thromb Vasc Biol* 2005;25:2368–2375.
- Bergmeyer HU, Hørdler M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). *J Clin Chem Clin Biochem* 1986;24:481–495.
- Rustad P, Felding P, Franzson L, Kairisto V, Lahti A, Martensson A, Hyltoft PP, Simonsen P, Steensland H, Uldall A: The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. *Scand J Clin Lab Invest* 2004;64:271–284.
- Solberg HE: RefVal: a program implementing the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values. *Comput Methods Programs Biomed* 1995; 48:247–256.
- Solberg HE, Grasbeck R: Reference values. *Adv Clin Chem* 1989;27:1–79.
- Rustad P, Felding P, Lahti A, Hyltoft Petersen P: Descriptive analytical data and consequences for calculation of common reference intervals in the Nordic Reference Interval Project 2000. *Scand J Clin Lab Invest* 2004; 64:343–370.
- Felding P, Rustad P, Mårtensson A, Kairisto V, Franzson L, Hyltoft Petersen P, Uldall A: Reference individuals, blood collection, treatment of samples and descriptive data from the questionnaire in the Nordic Reference Interval Project 2000. *Scand J Clin Lab Invest* 2004;64:327–342.